Drug-Induced Subacute Cutaneous Lupus Erythematosus: a Paradigm for Bedside-To-Bench Patient-Oriented Translational Clinical Investigation
Total Page：16
File Type：pdf, Size：1020Kb
Arch Dermatol Res (2009) 301:65–70 DOI 10.1007/s00403-008-0890-x REVIEW Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation Richard D. Sontheimer Æ Clifford L. Henderson Æ Renee H. Grau Received: 15 August 2008 / Accepted: 22 August 2008 / Published online: 17 September 2008 Ó Springer-Verlag 2008 Abstract At least 71 patients have been reported in which blockers, angiotensin converting enzyme (ACE) inhibitors, their otherwise typical subacute cutaneous lupus erythe- beta-blockers). An approach to the management of DI- matosus (SCLE) skin lesions were felt to have been SCLE is presented. Ro/SS-A autoantibodies tended to temporally associated with the systemic administration of a remain present in the blood after resolution of drug-induced drug. The mean age of this cohort of drug-induced SCLE SCLE skin lesions. A common link between the disparate (DI-SCLE) patients was 59 years of age which is somewhat group of drug structures implicated in triggering SCLE is older than the mean age of previously reported idiopathic their tendencies to produce photosensitivity and lichenoid SCLE patient cohorts. Patients had been taking the sus- drug reactions. This leads to the speculation that DI-SCLE pected triggering drug for weeks to years before the onset of could represent a photo-induced isomorphic/Ko¨ebner SCLE skin lesions. In addition, it was not unusual for 2– response in an immunogenetically predisposed host. 3 months to be required for resolution of the SCLE skin lesions following discontinuation of the triggering drug. A Keywords relatively large number of drugs representing different Drug-induced subacute cutaneous lupus erythematosus Á pharmacological classes have been implicated in the Bedside-to-bench patient-oriented translational clinical induction of SCLE. The drug classes that were more fre- investigation quently encountered were those used for the treatment of cardiovascular disease, especially hypertension. Calcium channel blockers were especially common in this regard. Introduction Elderly individuals being treated for hypertension are often taking multiple classes of drugs that have been implicated in David Nathan has defined the individual, typically a phy- triggering SCLE (thiazide diuretics, calcium channel sician, who performs ‘‘patient-based’’ clinical research as a patient-oriented translational clinical investigator (POT- CI) [11]. Two subtypes exist within the POTCI persona. R. D. Sontheimer (&) Á R. H. Grau One subtype focuses on translating the advances of basic Department of Dermatology, research into improved clinically practices (i.e., rendering Richard and Adeline Fleischaker Chair in Dermatology advances in basic science into better diagnostics and better Research, University of Oklahoma Health Sciences Center, treatments). This persona is typically referred to as the Oklahoma Medical Research Foundation, 619 N.E, 13th Street , Oklahoma City, OK 73104, USA ‘‘bench-to-bedside’’ POTCI. In this setting, POTCIs who e-mail: [email protected] are conversant with the language and literature of a basic R. H. Grau research discipline attempt to ‘‘translate’’ new research e-mail: [email protected] insights into better clinical practices for patients. The other patient-based clinical research subtype is the C. L. Henderson ‘‘bedside-to-bench’’ POTCI. This is typically a physician University of Oklahoma College of Medicine, Oklahoma City, OK, USA scholar who extends her/his professional effort to the gen- e-mail: [email protected] eration and publication of new knowledge by studying 123 66 Arch Dermatol Res (2009) 301:65–70 patients to whom they personally provide ‘‘hands-on’’ History of drug-induced SCLE (DI-SCLE) medical care. This is accomplished by careful subpheno- typing of disease(s) of interest through critical analysis of In 1985, Reed and coworkers at the University of Colorado epidemiologic, clinical and laboratory information. Clinical reported five patients whose otherwise typical SCLE skin specimens such as skin biopsy tissue, serum, DNA/RNA are lesions developed while taking hydrochlorothiazide. In all often collected from patients sharing homogeneous clinical five patients, the SCLE lesions resolved following hydro- subphenotypes of interest. This material is then examined in chlorothiazide discontinuation. SCLE lesions reappeared in a laboratory setting by the POTCI alone or in collaboration one patient that was re-challenged with hydrochlorothia- with physician scientists and/or basic scientists in order to zide. All five patients were positive for Ro/SS-A test a hypothesis that often has been generated by the bed- autoantibodies. Ro/SS-A autoantibodies disappeared in 1/3 side-to-bench POTCI. Such hypotheses address disease patients that were examined after resolution SCLE lesions classification, etiology, pathogenesis and/or improved following hydrochlorothiazide withdrawal. These workers treatment. When dealing with rare/orphan diseases, such hypothesized that thiazides might potentiate epidermal clinical information and specimens might be shared with keratinocyte cytotoxicity and that thiazides might also other bedside-to-bench POTCIs having similar interests at promote Ro/SS-A antibody production. other institutions in collaborative multicenter studies. However since then, a number of other seemingly The concept of subacute cutaneous lupus erythematosus unrelated classes of drugs have also been reported to be (SCLE) as we understand it today three decades after it’s capable of triggering DI-SCLE. To gain a broader per- original description in 1979 [18] has resulted largely from spective on the epidemiology, clinical and laboratory the combined efforts of many bedside-to-bench and bench- features, management, and prognosis of DI-SCLE, we to-bedside POTCIs around the world since then (contri- performed a systematic review of the published literature in butions reviewed in [3, 12, 16, 17]). The efforts of these this area through mid 2007. workers have established SCLE as a distinctive clinical, histopathologic, and immunogenetic subphenotype recog- nizable within the mosaic of LE (Fig. 1). Definition and epidemiology of DI-SCLE In this presentation we will highlight a clinical facet of the SCLE subphenotype that continues to evolve, drug- It should be noted that formal criteria for diagnosing DI- induced SCLE (DI-SCLE). A better understanding of this SCLE have yet to be formulated. The strongest evidence pattern of disease that has been brought to our attention by linking a drug to the induction of SCLE would be a positive many clinical scholars and bedside-to-bench POTCIs might challenge/provocation with the suspected drug after with- contribute to a better understanding of the etiopathogenesis drawal of the initially suspected drug had resulted in of idiopathic SCLE. A more comprehensive analysis of an resolution of the SCLE lesions. However, this has been extension of this data set through May, 2008 is being carried out only rarely in drug-induced SCLE patients. published separately [4]. Therefore, our only criterion for including cases of DI- SCLE in this review was the fact that proposed cases had withstood editorial and/or peer review during the publica- tion process. The large majority of cases were identified through PubMed/Medline searches. The Reference sections of the resulting publications were examined to identify additional cases published in journals not indexed by PubMed/ Medline. Our search strategy identified 71 published cases of DI- SCLE as of June, 2007. Each of these cases was presented as individual case reports or in small retrospective cases series. To date, no population-based data have been pre- sented concerning the epidemiology of DI-SCLE. The large majority of cases were Caucasian females. The mean age of the DI-SCLE cases identified in this review was 59.5 years. The time range between starting the Fig. 1 SCLE as a subphenotype of LE. SCLE can be viewed as a triggering drug and the first appearance of SCLE lesions distinctive subphenotype within the mosaic of LE recognizable by its combination of characteristic clinical, histopathologic, and immuno- (i.e., the ‘‘incubation period’’) was 2 weeks–3.2 years. The genetic features mean time to clearance of lesions after the suspected 123 Arch Dermatol Res (2009) 301:65–70 67 triggering drug was discontinued was 5.76 weeks with a Relationship between DI-SCLE and DI-SLE range of 1-24 weeks (i.e., ‘‘resolution period’’). There were not enough data reported to determine whether different It is curious that the classes of drugs that have been drug classes exhibited different incubation periods and reported to induce SCLE have little overlap with those that resolution periods. have traditionally been associated with drug-induced sys- temic LE [15]. Perhaps this reflects fundamental differences in the pathogenesis of these two patterns of Drugs implicated in DI-SCLE drug-induced LE. This is supported by the facts that the classical form of drug-induced systemic LE rarely includes Table 1 presents the various systemic therapeutic agents lupus-specific skin changes such as SCLE and clinically listed alphabetically by category that our search strategy significant internal manifestations of systemic LE have found to have been reported to be associated with the been absent to minimal in DI-SCLE cases reported to date. induction of SCLE skin lesions. Interestingly, almost half of these drugs are primarily used for the treatment